After first-line treatment attempts with antidepressant medication, patients are often forced to pursue more pharmacotherapy. Few depression treatment options have been studied and approved by the FDA for use in patients who have not benefited from prior antidepressant treatment.

Results from the STAR*D Study

  • The likelihood of achieving remission is limited and declines with each successive treatment attempt12,13,14,15
  • The likelihood of discontinuing treatment increases with each new treatment attempt12,14

As Medication Increases, So Can Side Effects and the Potential for Treatment Failure12,13,14,15

Depression treatment adherence and effectiveness

TMS—An Appropriate Option for Depression Treatment3

In the 3rd edition of Practice Guideline for the Treatment of Patients with Major Depression (2010), the American Psychiatric Association (APA) cited TMS as an appropriate treatment option for depression patients who have not benefited from initial antidepressant pharmacotherapy.

APA Depression Practice Guidelines options for the treatment of depression3

APA Depression Practice Guidelines

Several other organizations have also acknowledged the scientific evidence for the safety and efficacy of TMS, including:

  • The World Federation of Societies for Biological Psychiatry (2009)
  • The Canadian Network for Mood and Anxiety Treatments (2009)

Find out who may be an appropriate candidate for NeuroStar TMS Therapy®

View a video on the benefits of TMS Therapy

NeuroStar® Efficacy